Antisera against a PEB1 antigen from Campylobacter jejuni |
| It is an object of the present invention to provide highly specific and highly sensitive diagnostic ... |
|
Gene encoding invasion protein of campylobacter species |
| OF PREFERRED EMBODIMENTS The following standard abbreviations for the amino acid residues are used ... |
|
Preservatives for vaccines |
| New combinations of preservatives that pass antimicrobial testing requirements for United States P... |
|
Methods and reagents for HLA class I A locus DNA typing |
| OF THE INVENTION To aid in understanding the invention, several terms are defined below. The terms ... |
|
Immunomodulating compounds comprising d-isomers of amino acids |
| What is claimed is: 1. A peptide compound having immunomodulating activity comprising the sequence: ... |
|
Targeted destruction of pests |
| The present invention is drawn to a safe, cost-effective, environmentally-friendly and ecologically-... |
|
Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| OF THE INVENTION U.S. patents, U.S. patent application publications, U.S. patent applications, ... |
|
Intercellular adhesion molecule--2 and its binding ligands |
| What is claimed is: 1. A method for treating inflammation in a mammalian subject which comprises ... |
|
E2 subunit vaccine comprising recombinant pestivirus E2 protein |
| 1. An E2 subunit vaccine comprising recombinant Classical Swine Fever Virus (CSFV) E2 glycoprotein ... |
|
Fibronectin binding protein-encoding DNA |
| We claim: 1. Plasmid pSDF102 as contained in the E. coli TG1 strain, having the deposit number DSM 4... |
|
|
Vaccine against the sporozoite stage of malaria
| Details |
Inventors: Nussenzweig, Victor; Barr, Philip;
Assignee: New York University (New York, NY); Chiron Corporation (Emeryville, CA)
Primary Examiner: Lee; Lester L.
Assistant Examiner:
Attorney, Agent or Firm: Darby & Darby
Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast. |
|
DETAILED DESCRIPTION OF THE INVENTION The P. vivax CS gene is set forth below (together with the amino acid sequence for which its codes) ##STR1## The DNA fragment chosen for insertion in the yeast host was; ##STR2## This fragment includes the entire tandem repeat sequence plus a region that is substantially parallel to Region I of Dame, et al Science 225:628 (1984), precedes the repeat region, and codes for the amino acid sequence A E P K N P R E N K L K Q P G. This sequence includes the subsequence K L K Q P which is conserved in all molarial species that have been investigated to data. The foregoing DNA fragment was obtained from the entire gene by subcloning a 15kb BllII fragment isolated as described by Arnot et al (U. S. Pat. Ser. No. 754,645, and Science 230:815-818, Nov. 15, 1985) both incorporated by reference. It was then inserted in the DNA of modified yeast plasmid pAB24 as described in Example 1 below. For expression of the P. vivax CS antigen in yeast, a hybrid promoter comprising the strong yeast glyceraldehyde-3-phosphate dehydrogenase and the glucose regulatable alcohol dehydrogenase-2 (ADH-2) promoter was used. Fusion of this promoter to heterologous genes allows the growth of yeast cultures to high density using glucose as a carbon source. Depletion of glucose in the media during fermentative growth leads to concomitant induction of expression of the heterologous protein. Incorporation of the plasmid into high copy number, autonomously replicating yeast plasmids, and transformation of yeast cells generated strains capable of expressing high levels of CS proteins on induction. The yeast was grown in culture in YEP medium (1% w/v yeast extract, 2% peptone) with 1% glucose as described in Example 1 below. Two hundred liters of yeast material were thus obtained and stored at -80. degree. C. The thus obtained yeast material contained a complex mixture of different yeast proteins as well as culture medium additives. Gel electrophoresis of this material on 7. 5% sodium dodecyl sulfate polyacrylamide gel gave an indication of its heterogeneity (see FIG
|
| Related patents |
|
|
Malaria antigen
We claim: 1. A substantially pure polypeptide comprising the amino acid sequence of a glutamate-rich polypeptide (GLURP) derived from a Plasmodium falciparum antigen ("...
|
|
|
Oligopeptide lyophilisate, their preparation and use
OF PREFERRED EMBODIMENTS The following Examples illustrate the invention. EXAMPLE 1 Approx. 1.5 liters of water for injection purposes are prepared in a suitable glass ...
|
|
|
Antithrombin nucleotides and proteins from horn fly
Isolated proteins with antithrombin activity and nucleotide sequences encoding the proteins are provided. The protein named thrombostasin is isolated from the salivary ...
|
|
|
Immunogenic conjugates comprising leukotoxin peptide fragments
OF THE INVENTION Substances having molecular weights less than 1000 daltons are not ordinarily antigenic. However, antibodies can be raised to small molecules by ...
|
|
|
Interleukin-2-leukotoxin gene fusions and uses thereof
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
GnRH-leukotoxin chimeras
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
GNRH-leukotoxin chimeras
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
Polynucleotides encoding LKT 111
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
Methods and compositions for the treatment of defects in lipoprotein metabolism
In one aspect, the invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which ...
|
|
|